1-14 of 14
Keywords: therapy
Close
Sort by
Articles
Biochem Soc Trans (2024) 52 (3): 1275–1291.
Published: 30 May 2024
... and is also associated with side effects and a loss of efficacy over time. We present ongoing efforts to reinforce the effect of levodopa and to develop innovative therapies that target the underlying pathogenic mechanisms affecting DA synthesis and transport, increasing neurotransmission through disease...
Articles
Biochem Soc Trans (2021) 49 (4): 1803–1816.
Published: 26 August 2021
...Paola Fulghieri; Lucia Anna Stivala; Virginie Sottile Cancer has been traditionally viewed as a disease characterised by excessive and uncontrolled proliferation, leading to the development of cytotoxic therapies against highly proliferating malignant cells. However, tumours frequently relapse due...
Articles
Articles
Biochem Soc Trans (2012) 40 (1): 31–36.
Published: 19 January 2012
... that make the ATX–LPA signalling axis an emerging target for cancer therapy. To extend these in vitro observations, we injected 5×10 5 Scr- and ShATX-transduced B16 melanoma cells into C57BL/6 mice via the tail vein. At 3 weeks post-inoculation, animals were killed, the lungs were washed, inflated...
Articles
Biochem Soc Trans (2011) 39 (6): 1612–1618.
Published: 21 November 2011
...Chern Ein Oon; Adrian L. Harris Notch signalling is a key pathway controlling angiogenesis in normal tissues and tumours. This has become a major focus of development of anticancer therapy, but to develop this appropriately, we need further understanding of the mechanisms of regulation of Dll4...
Articles
Biochem Soc Trans (2010) 38 (2): 343–347.
Published: 22 March 2010
...Qizhi Huang; Laura J. Hardie Biomarkers are needed to screen multiple stages in the clinical pathway of Barrett's oesophagus patients; from disease diagnosis to risk stratification and predicting response to therapy. Routes to the identification of biomarkers have been recognized by known molecular...
Articles
Biochem Soc Trans (2008) 36 (6): 1304–1308.
Published: 19 November 2008
... with the involvement of metal ions. Chelation therapy could provide a valuable therapeutic approach to such disease states, since metals, particularly iron, are realistic pharmacological targets for the rational design of new therapeutic agents. 1 To whom correspondence should be addressed (email robert.hider...
Articles
Biochem Soc Trans (2007) 35 (2): 411–415.
Published: 20 March 2007
...) small hairpin RNA (shRNA) target validation therapy Disorders of the central nervous system are among the most complex, poorly understood, and debilitating diseases. The burgeoning advances in functional genomic technologies have led to the identification of a vast number of novel genes...
Articles
Biochem Soc Trans (2007) 35 (2): 416–420.
Published: 20 March 2007
.... 1 To whom correspondence should be addressed (email [email protected] ). 5 10 2006 © 2007 The Biochemical Society 2007 Alzheimer's disease β-amyloid-cleaving enzyme (BACE) amyloid precursor protein (APP) amyloid precursor-like protein (APLP) γ-secretase therapy...
Articles
Biochem Soc Trans (2006) 34 (2): 313–316.
Published: 20 March 2006
... will play an even more vital role in the generation of future therapies. Scheme 1 The impact of molecular biology on the drug-discovery process An overview of the process of drug discovery illustrating where molecular biology plays a significant role. HTS, high-throughput screening...
Articles
Biochem Soc Trans (2003) 31 (4): 768–769.
Published: 01 August 2003
...H. Valdimarsson Our first experience of mannan-binding lectin (MBL)-replacement therapy was with a patient experiencing recurrent erythema multiforme associated with reactivation of herpes simplex virus; his erythematous eruptions could be controlled with infusions of fresh frozen plasma containing...
Articles
Biochem Soc Trans (2003) 31 (4): 770–773.
Published: 01 August 2003
... the natural history of (e.g. rheumatoid arthritis, cystic fibrosis), a disease. MBL (plasma-derived or recombinant) therapy has yet to be shown to be safe and effective. Potentially it may be useful in MBL-deficient patients to reduce susceptibility to, or enhance recovery from, bacterial infection...
Articles
Biochem Soc Trans (2003) 31 (4): 763–767.
Published: 01 August 2003
... Biochemical Society 2003 complement innate immunity mannan-binding lectin (MBL) recombinant mannan-binding lectin therapy Abbreviations used: MBL, mannan-binding lectin; pMBL, plasma-derived MBL; rMBL, recombinant MBL; MASP, MBL-associated serine protease; MALDI-MS, matrix-assisted laser...
Articles
Biochem Soc Trans (2002) 30 (6): 1019–1026.
Published: 01 November 2002
... therapy in disease. Here we will review the development of anticomplement therapeutics from the first generation agents, which are unmodified recombinant forms of natural regulators, to recent strategies for making better drugs. We will describe strategies for targeting the anticomplement activity...